Page last updated: 2024-11-04

fructose-1,6-diphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

beta-D-fructofuranose 1,6-bisphosphate : A D-fructofuranose 1,6-bisphosphate with a beta-configuration at the anomeric position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

fructose-1,6-diphosphate: RN refers to (D)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10267
CHEMBL ID97893
CHEBI ID28013
SCHEMBL ID168244
MeSH IDM0092971
PubMed CID46937007
SCHEMBL ID168245
MeSH IDM0092971

Synonyms (44)

Synonym
CHEMBL97893
beta fructose 1,6-diphosphate
fructose 1,6-diphosphate
beta-d-fructofuranose 1,6-bisphosphate
1,6-di-o-phosphono-beta-d-fructofuranose
beta-d-fructofuranose 1,6-bis(dihydrogen phosphate)
CHEBI:28013 ,
d-fructose-1,6-diphosphate
beta-d-fructose-1,6-diphosphate
beta-d-fructofuranose, 1,6-bis(dihydrogen phosphate)
34693-15-7
beta-fructose-1,6-diphosphate
C05378
beta-d-fructose 1,6-bisphosphate
FBP ,
DB04551
1BO5
NCGC00166321-01
fructose-1,6-bisphosphate
16EB39BB-B854-429F-972F-0D8401178A36
[(2r,3s,4s,5r)-2,3,4-trihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]methyl dihydrogen phosphate
BMSE000011
einecs 251-977-7
SCHEMBL168244
DTXSID0048347
RNBGYGVWRKECFJ-ARQDHWQXSA-N
d-fructose 1,6-biphosphate
.beta.-d-fructofuranose, 1,6-bis(dihydrogen phosphate)
diphosphofructose
esafosfan
fructose bisphosphate
d-fructose-1,6-bisphosphate
d-fructose 1,6-diphosphate
esafosfina
fructose 1,6-bis
Q414945
beta-d-fructofuranose 1,6-bisphosphate (rssr closed ring)
.beta.-d-fructofuranose 1,6-diphosphate
.beta.-d-fosfructofuranose
WCH874XLB1
bdbm50597704
fructose-1,6-diphosphate
SCHEMBL168245
Q27095310

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Use of cyclosporin A (CsA) in transplantation medicine has been shown to cause a number of toxic cellular side effects, which has prompted a search for formulations that afford protection from these undesirable sequelae."( Myocardial toxicity of cyclosporin A: inhibition of calcium ATPase and nitric oxide synthase activities and attenuation by fructose-1,6-diphosphate in vitro.
Hutcheson, AE; Markov, AK; Olinde, KD; Rao, MR, 1995
)
0.29
" Though it was not possible to elucidate the toxic mechanism of FBP, the electrocardiogram (ECG) showed that all the rats died of cardiac arrest."( Intravenous toxicity of fructose-1,6-bisphosphate in rats.
Alves Filho, JC; Avila, LD; Biolchi, V; de Assis, M; De Oliveira, JR; Gaspareto, PB; Graziottin, CM; Lunardelli, A; Nunes, FB; Pires, MG; Santos, RC; Wächter, PH, 2003
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic profiles of Sr-FDP were investigated in Sprague-Dawley rats following oral administration at a dose of 110, 220, and 440mg/kg respectively."( Synthesis and pharmacokinetics of strontium fructose 1,6-diphosphate (Sr-FDP) as a potential anti-osteoporosis agent in intact and ovariectomized rats.
Hu, Y; Ma, B; Shaw, JP; Wang, G; Wang, Y; Wu, Z; Yang, Z; Ying, H; Zhang, Q; Zheng, Y, 2011
)
0.37
" Then, the pharmacokinetic studies were performed following multiple doses of FDP in rats, and the Caco-2 monolayer model was used to study the absorption of FDP in vitro."( Rational application of fructose-1,6-diphosphate: From the perspective of pharmacokinetics.
Gao, YY; Jiang, XH; Li, TT; Wang, L; Xie, JZ, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
"Fructose-1,6-diphosphate (FDP) reduces postischemic reperfusion injury and is used alone and in combination with cyclosporine A (CsA) as an immunosuppressant."( Fructose-1,6-diphosphate alone and in combination with cyclosporine potentiates rat cardiac allograft survival and inhibits lymphocyte proliferation and interleukin-2 expression.
Cohly, HH; Heath, B; Markov, AK; Moore, C; Netherland, DE; Rayburn, TS; Talton, DS, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Ischemic phase damage was addressed by comparing the dose-response effects of controls vs."( Effect of high-energy phosphates and free radical scavengers on replant survival in an ischemic extremity model.
Ablove, RH; Moy, OJ; Peimer, CA; Severin, CM; Sherwin, FM, 1996
)
0.29
" The other control animals received the same dosage of 10% dextrose."( Fructose-1,6-diphosphate in the treatment of oleander toxicity in dogs.
Hume, AS; Lehan, PH; Markov, AK; Markov, MA; Payment, MF; Rao, MR; Skelton, TN, 1999
)
0.3
" We designed a randomized, placebo-controlled, double-blinded, sequential-cohort, dose-ranging safety study to test 5 FDP dosage regimens in patients (n = 120; 60 FDP, 60 control) undergoing CABG surgery."( Myocardial protection using fructose-1,6-diphosphate during coronary artery bypass graft surgery: a randomized, placebo-controlled clinical trial.
Ellis, G; Fox, AW; Gal, J; Marangos, PJ; Riedel, BJ; Royston, D, 2004
)
0.32
" However, further research is warranted for a reasonable and effective dosage of FDP."( [Protective effect of fructose-1,6-diphosphate against ultrastructural damage in the hippocampus of rats with repeated febrile seizures].
Huang, SP; Li, RL; Wang, F; Yang, L; Zhou, JP, 2008
)
0.35
" In addition, we describe acute effect of CS-917 on fasting hyperglycemia in overnight-fasted GK rats and chronic effect of CS-917 in multiple dosing GK rats."( CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
Fujiwara, T; Hagisawa, Y; Izumi, M; Ohsumi, J; Okuno, A; Takahashi, K; Yoshida, T, 2008
)
0.35
" Verapamil-poisoned rats received the higher dosing regimen of FDP250."( The effects of fructose-1,6-diphosphate on haemodynamic parameters and survival in a rodent model of propranolol and verapamil poisoning.
Graudins, A; Kalam, Y, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
D-fructofuranose 1,6-bisphosphateThe furanose form of D-fructose 1,6-bisphosphate.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (16)

PathwayProteinsCompounds
Aerobic glycolysis020
Metabolic Epileptic Disorders2589
Central carbon metabolism019
Relationship between glutathione and NADPH036
Hexoses metabolism in proximal tubules016
Fructose and mannose metabolism014
Glycolysis010
Turbo design of glycolysis06
Primary carbon metabolism2330
Starch metabolism09
AtMetExpress overview0109
Glycolysis and Gluconeogenesis08
Cori cycle121
HIF1A and PPARG regulation of glycolysis07
Biochemical pathways: part I0466
Metabolic reprogramming in colon cancer029
Glycolysis and gluconeogenesis017

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency40.53340.007215.758889.3584AID624030
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain O, Protein (glycerol Kinase)Escherichia coliKi250.0000250.0000250.0000250.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pyruvate kinase PKMHomo sapiens (human)EC50 (µMol)0.02300.00050.59206.0000AID1881862
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
programmed cell deathPyruvate kinase PKMHomo sapiens (human)
canonical glycolysisPyruvate kinase PKMHomo sapiens (human)
positive regulation of sprouting angiogenesisPyruvate kinase PKMHomo sapiens (human)
positive regulation of cytoplasmic translationPyruvate kinase PKMHomo sapiens (human)
glycolytic processPyruvate kinase PKMHomo sapiens (human)
cellular response to insulin stimulusPyruvate kinase PKMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
magnesium ion bindingPyruvate kinase PKMHomo sapiens (human)
RNA bindingPyruvate kinase PKMHomo sapiens (human)
mRNA bindingPyruvate kinase PKMHomo sapiens (human)
protein tyrosine kinase activityPyruvate kinase PKMHomo sapiens (human)
pyruvate kinase activityPyruvate kinase PKMHomo sapiens (human)
protein bindingPyruvate kinase PKMHomo sapiens (human)
ATP bindingPyruvate kinase PKMHomo sapiens (human)
MHC class II protein complex bindingPyruvate kinase PKMHomo sapiens (human)
potassium ion bindingPyruvate kinase PKMHomo sapiens (human)
cadherin bindingPyruvate kinase PKMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionPyruvate kinase PKMHomo sapiens (human)
nucleusPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
mitochondrionPyruvate kinase PKMHomo sapiens (human)
rough endoplasmic reticulumPyruvate kinase PKMHomo sapiens (human)
cytosolPyruvate kinase PKMHomo sapiens (human)
ciliumPyruvate kinase PKMHomo sapiens (human)
vesiclePyruvate kinase PKMHomo sapiens (human)
secretory granule lumenPyruvate kinase PKMHomo sapiens (human)
collagen-containing extracellular matrixPyruvate kinase PKMHomo sapiens (human)
extracellular exosomePyruvate kinase PKMHomo sapiens (human)
extracellular vesiclePyruvate kinase PKMHomo sapiens (human)
ficolin-1-rich granule lumenPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID30432Compound was tested for inhibition of Human acrosin by phosphorylated monosaccharides1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Inhibition of human acrosin by monosaccharides and related compounds: structure-activity relationships.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID68943Enzymatic kinetics (Km) constant towards FBP aldolase from rabbit2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
New highly selective inhibitors of class II fructose-1,6-bisphosphate aldolases.
AID68937Enzymatic kinetics (Km) constant towards FBP aldolase from Bacillus subtilis2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
New highly selective inhibitors of class II fructose-1,6-bisphosphate aldolases.
AID68940Enzymatic kinetics (Km) constant towards FBP aldolase from yeast2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
New highly selective inhibitors of class II fructose-1,6-bisphosphate aldolases.
AID1881862Activation of PKM2 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID1811Experimentally measured binding affinity data derived from PDB1998Biochemistry, Nov-24, Volume: 37, Issue:47
Crystal structure of a complex of Escherichia coli glycerol kinase and an allosteric effector fructose 1,6-bisphosphate.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1998Biochemistry, Nov-24, Volume: 37, Issue:47
Crystal structure of a complex of Escherichia coli glycerol kinase and an allosteric effector fructose 1,6-bisphosphate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (869)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990266 (30.61)18.7374
1990's242 (27.85)18.2507
2000's197 (22.67)29.6817
2010's149 (17.15)24.3611
2020's15 (1.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials20 (2.23%)5.53%
Reviews0 (0.00%)6.00%
Reviews18 (2.01%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies8 (0.89%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other851 (94.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]